Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2019-11-20 Regulatory Filings
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
New European Moditope patent allowed for grant
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and is dated '20 November 2019'. It contains a headline announcing a patent grant and a presentation schedule. The footer explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure and explicit source identification strongly indicate a general regulatory news service announcement, which corresponds to the 'Regulatory Filings' category (RNS). It is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/board change (MANG).
2019-11-20 English
Directorate Change
Board/Management Information Classification · 99% confidence The document begins with an 'RNS Number' and is dated October 23, 2019. The core content announces a 'Directorate Change,' specifically the appointment of Dr. Ursula Ney as a Non-Executive Director and the stepping down of Dr. Matthew Frohn. This directly relates to changes in the company's board of directors or senior management. This aligns perfectly with the definition for Board/Management Information (MANG). Although it is distributed via RNS, the specific subject matter dictates the MANG classification over the general RNS fallback.
2019-10-23 English
Group of companies' accounts made up to 2019-04-30
Regulatory Filings
2019-10-03 English
Posters at Cancer Immunotherapy Conference
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and is dated September 26, 2019. The content announces that Scancell Holdings plc will be presenting posters at an international cancer immunotherapy conference. This is a specific operational update regarding scientific dissemination, not a comprehensive financial report (like 10-K or IR), a formal earnings release (ER), or a proxy statement. Since it is a formal announcement disseminated via RNS (London Stock Exchange's news service) that doesn't fit into the more specific categories like DIV, DIRS, or MANG, it falls best under the general Regulatory Filings category (RNS) as a specific corporate/scientific update released through the regulatory channel.
2019-09-26 English
Result of AGM
AGM Information Classification · 99% confidence The document explicitly states 'Result of AGM' and confirms that 'all resolutions proposed at the Annual General Meeting were duly passed.' This directly relates to the outcome of an Annual General Meeting. Although it mentions the AGM, the core content is the announcement of the results of the shareholder vote, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' (DVA). However, since the document is a formal regulatory announcement disseminated via RNS (indicated by the RNS Number and footer), and the result itself is the primary focus, AGM-R (AGM Information) is also highly relevant. Given the specific nature of reporting the *result* of the vote, DVA is the most precise fit for the action described, although AGM-R covers the event itself. Since the text is a brief announcement of the outcome, and not the presentation materials (AGM-R) or the proxy materials (PSI), DVA is the strongest classification for reporting the vote outcome.
2019-09-12 English
First Collaboration Agreement for AvidiMab
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's RNS service. The content describes a significant business event: signing a collaboration agreement for a new technology platform (AvidiMab™). This type of announcement, detailing strategic partnerships, pipeline progress, and containing boilerplate regulatory disclaimers ('This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)'), is characteristic of a general regulatory news service release. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific shareholder vote result (DVA), the most appropriate classification is the general regulatory filing category, RNS.
2019-09-04 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.